Pyxis Oncology Expands PYX-201 Clinical Program with New Combination Trial and Monotherapy Cohorts
核心洞察
Pyxis Oncology launches Phase 1/2 trial evaluating PYX-201 in combination with pembrolizumab across multiple advanced solid tumors, including HNSCC, TNBC, and gastric cancer (搜索).
The company initiates expansion cohorts in its ongoing Phase 1 PYX-201 monotherapy trial, focusing on second and third-line HNSCC patients with prior platinum and PD-1 inhibitor treatment.
PYX-201, an antibody-drug conjugate targeting EDB+FN (搜索) in the tumor microenvironment, represents a novel approach to treating difficult-to-treat cancers.
Pyxis Oncology has significantly expanded its clinical development program for PYX-201, marking a crucial advancement in its mission to combat difficult-to-treat cancers. The company has launched two major clinical initiatives that broaden the therapeutic potential of their lead antibody-drug conjugate candidate.
New Combination Trial with Pembrolizumab
The company has initiated PYX-201-102, a Phase 1/2 global, multicenter study investigating PYX-201 in combination with pembrolizumab. This open-label trial will evaluate the safety, tolerability, and preliminary efficacy across multiple advanced solid tumors. The study encompasses several patient populations, including:
- First-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
- Advanced or metastatic triple-negative breast cancer (TNBC)
- Hormone receptor-positive and HER2-negative breast cancer
- Gastric cancer
- Cervical cancer
- Second-line and higher recurrent/metastatic HNSCC
Expansion of Monotherapy Program
Simultaneously, Pyxis has initiated Part 2 expansion cohorts in its ongoing Phase 1 PYX-201-101 monotherapy trial. The expansion phase is focusing on two specific patient populations:
- Second and third-line recurrent/metastatic HNSCC patients previously treated with platinum and PD-1 inhibitor therapy
- Second and third-line recurrent/metastatic HNSCC patients who have received prior EGFR and PD-1 inhibitor therapy
Innovative Therapeutic Approach
PYX-201 represents a novel approach in oncology therapeutics. The antibody-drug conjugate is designed to target Extradomain-B Fibronectin (EDB+FN (搜索)), a structural component of the tumor extracellular matrix. The drug employs an optimized auristatin payload that acts as a microtubule inhibitor, directly attacking cancer cells while addressing factors in the tumor microenvironment that contribute to cancer growth and immune evasion.
Strategic Clinical Development
The dual-track development strategy - evaluating both monotherapy and combination approaches - demonstrates Pyxis Oncology's comprehensive approach to maximizing PYX-201's therapeutic potential. The trials are being conducted across sites in the United States, European Union, and other countries, reflecting the global scope of this clinical program.
This expanded clinical program represents a significant milestone in Pyxis Oncology's mission to develop innovative therapies for cancer patients with limited treatment options. The company's focus on both monotherapy and combination approaches, coupled with its novel targeting mechanism, positions PYX-201 as a potential breakthrough treatment across multiple cancer types.